A efficacy of maintenance intensification therapy by(Bevacizumab)/Pemetrexed/Carboplatin or Cisplatin after induction therapy by Erlotinib for EGFR mutation positive non -spuamous non-small cell lung cancer.

A efficacy of maintenance intensification therapy by(Bevacizumab)/Pemetrexed/Carboplatin or Cisplatin after induction therapy by Erlotinib for EGFR mutation positive non -spuamous non-small cell lung cancer. - A efficacy of maintenance intensification therapy by(Bevacizumab)/Pemetrexed/Carboplatin or Cisplatin after induction therapy by Erlotinib for EGFR mutation positive non -spuamous non-small cell lung cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013125

Enrollment

Registered

2014-02-10

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small non-squamous cell lung cancer

Interventions

Pemetrexed Platinum-Doublet Erlotinib (Bevacizumab)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically or cytologically proven non-squamous non-small cell lung cancer 2)at least one measurable leision (RECIST) 3)stageIII/IV or recurrent post-operative non-squamous and non-small cell lung cancer 4)EGFR mutaion positive 5)1. PS:0-2 (ECOG) (before Erlotinib),2. PS:0-1 (ECOG) (before Chemotherapy), 6)Patients aged 20 or over, 80 under 7)adequate bone marrow,liver,and renal functions 8)written informed consent

Exclusion criteria

Exclusion criteria: 1)Patients with active infection 2)Patients with interstitial pneumonia by X ray or CT scan 3)severe complication

Design outcomes

Primary

Measure	Time frame
1-year Progression Free Survival rate	—

Countries

Japan

Contacts

Public ContactTetsuo Tani

School of Medicine, Keio University, Tokyo, Japan Department of Pulmonary Medicine

t.tani@z3.keio.jp0333531211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026